For menin inhibitor-naive cases, NPM1-mutated AML achieved CRc rates of 80% at a 200 mg dose and 50% at 400 mg, while KMT2Ar AML showed lower response rates of 29% and 17% at respective doses [32]. The gene discussed is MEN1; the disease is acute myeloid leukemia.